Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label nilotinib study in newly diagnosed chronic phase chronic myeloid leukemia
2012-005062-34Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Rate of CD34+/lin- Ph+ cells in bone marrow at 6 months. Started Dec 2012; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-005062-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005062-34.